These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27277955)

  • 1. An Infant with a Prolonged Sympathomimetic Toxidrome after Lisdexamfetamine Dimesylate Ingestion.
    Wood KE; Krasowski MD
    J Med Toxicol; 2016 Dec; 12(4):402-405. PubMed ID: 27277955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case series involving young children presenting with accidental ingestion of amphetamine based stimulants.
    Wood KE; McCarthy PJ; Krasowski MD
    Toxicol Rep; 2018; 5():1129-1133. PubMed ID: 30510906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
    Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
    Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.
    Faraone SV
    Expert Opin Pharmacother; 2008 Jun; 9(9):1565-74. PubMed ID: 18518785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
    Krishnan SM; Pennick M; Stark JG
    Clin Drug Investig; 2008; 28(12):745-55. PubMed ID: 18991468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study.
    Strajhar P; Vizeli P; Patt M; Dolder PC; Kratschmar DV; Liechti ME; Odermatt A
    J Steroid Biochem Mol Biol; 2019 Feb; 186():212-225. PubMed ID: 30381248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults.
    Mattingly G
    CNS Spectr; 2010 May; 15(5):315-25. PubMed ID: 20448522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
    Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
    J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.
    Ermer JC; Pennick M; Frick G
    Clin Drug Investig; 2016 May; 36(5):341-56. PubMed ID: 27021968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
    Ermer JC; Dennis K; Haffey MB; Doll WJ; Sandefer EP; Buckwalter M; Page RC; Diehl B; Martin PT
    Clin Drug Investig; 2011; 31(6):357-70. PubMed ID: 21539403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC-MS/MS.
    Comiran E; Barreto F; Meneghini LZ; Carlos G; Fröehlich PE; Limberger RP
    Biomed Chromatogr; 2017 Mar; 31(3):. PubMed ID: 27518755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.
    Najib J; Wimer D; Zeng J; Lam KW; Romanyak N; Paige Morgan E; Thadavila A
    J Cent Nerv Syst Dis; 2017; 9():1179573517728090. PubMed ID: 28855799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine.
    Comiran E; Carlos G; Barreto F; Pechanksy F; Fröehlich PE; Limberger RP
    Biopharm Drug Dispos; 2021 Jan; 42(1):3-11. PubMed ID: 33119133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
    Wigal SB; Jun A; Wong AA; Stehli A; Steinberg-Epstein R; Lerner MA
    Postgrad Med; 2010 Sep; 122(5):27-34. PubMed ID: 20861585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults.
    Faison SL; Fry N; Adewole T; Odebo O; Wang Z; Maletic V; Nasser A
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):155-162. PubMed ID: 33587403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.